GSK Files Seretide For COPD

UK drug major GlaxoSmithKline (GSK) has filed its salmeterol + fluticasone propionate combination drug for Chronic Obstructive Pulmonary Disorder (COPD) in Japan. The inhalable product is more widely branded as the leading asthma treatment Advair/Seretide, and the new indication is expected to boost sales in Japan, at a time when the niche market for COPD therapies is expanding globally. The drug was filed for its core indication of adult and paediatric bronchial asthma in

To read the full article, please choose one of the following options: